Artivion, Inc. (AORT)
| Market Cap | 742.93M |
| Revenue (ttm) | 304.96M |
| Net Income (ttm) | -15.09M |
| Shares Out | 40.20M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | 357.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 332,888 |
| Open | 18.31 |
| Previous Close | 18.26 |
| Day's Range | 18.20 - 19.12 |
| 52-Week Range | 15.44 - 31.78 |
| Beta | 1.55 |
| Analysts | Buy |
| Price Target | 28.76 (+55.6%) |
| Earnings Date | May 5, 2022 |
About AORT
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment...
Financial Performance
In 2021, Artivion's revenue was $298.84 million, an increase of 18.01% compared to the previous year's $253.23 million. Losses were -$14.83 million, -11.08% less than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for AORT stock is "Buy." The 12-month stock price forecast is 28.76, which is an increase of 55.63% from the latest price.
News
Artivion to Participate in the UBS 2022 Global Healthcare Conference
ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS...
Artivion Reports First Quarter 2022 Financial Results
Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLANTA...
ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results
ATLANTA, April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results w...
Artivion to Participate in the 21st Annual Needham Virtual Healthcare Conference
ATLANTA, March 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming 21...
Artivion Publishes Inaugural Corporate Responsibility Report
ATLANTA, March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Repo...
Artivion to Host Investor & Analyst Day on March 23, 2022
ATLANTA, March 9, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will host an Investor & Analyst Day ...
Artivion to Participate in the Oppenheimer 32nd Annual Healthcare Conference
ATLANTA, March 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the up...
Artivion (AORT) Reports Break-Even Earnings for Q4
Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Artivion Reports Fourth Quarter and Full Year 2021 Financial Results
ATLANTA, Feb. 17, 2022 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth quarter of 20...
Earnings Preview: Artivion (AORT) Q4 Earnings Expected to Decline
Artivion (AORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2021 Financial Results
ATLANTA, Feb. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2021 financ...
CryoLife Announces Corporate Rebranding and Changes Name to Artivion
ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to...
A Trio of Low Price-Sales Ratio Stocks
Value investors may find the following stocks to be attractive opportunities, as they have low price-sales ratios compared to the S&P 500 and good profitability.
CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-on...
Wall Street Analysts Think CryoLife (CRY) Could Surge 51%: Read This Before Placing a Bet
The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...
CryoLife (CRY) Tops Q3 Earnings Estimates
CryoLife (CRY) delivered earnings and revenue surprises of 420.00% and -0.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Cryolife Q3 Earnings
Cryolife (NYSE:CRY) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
CryoLife Reports Third Quarter 2021 Financial Results
ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, ...
Earnings Preview: CryoLife (CRY) Q3 Earnings Expected to Decline
CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results
ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results wil...
Anthony Semedo Joins CryoLife Board of Directors
ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to ...
CryoLife to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
ATLANTA, Aug. 31, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Morg...
CryoLife to Participate in Upcoming Virtual Investor Conferences
ATLANTA, Aug. 2, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtu...
CryoLife (CRY) Reports Q2 Loss, Tops Revenue Estimates
CryoLife (CRY) delivered earnings and revenue surprises of -20.00% and 5.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cryolife: Q2 Earnings Insights
Shares of Cryolife (NYSE:CRY) rose 2.9% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 700.00% year over year to $0.12, which beat the estimate ...